UK Clinical Vaccine Network Conference 2022

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

It is with great excitement that we can announce this year’s Clinical Vaccine Network Conference will be held in person at the Royal College of Physicians, London.

Hosted on the 30th June, this event will cover a wide spectrum of issues in vaccine development, presentations on the latest research, and the future of vaccines.

Whilst this conference will be made available to join virtually we thoroughly recommend attending in person to not miss out on this excellent networking opportunity. There will be an array of UK healthcare professionals, and other relevant decision makers who have a specific interest in vaccine intervention in the patient pathway.

Please share the flyer for the event available here with your colleagues.

If you have any queries, or would like to enquire about sponsorship of this event, please contact: debbie@pagemedical.co.uk.

@CVN_UK

Seqirus has sponsored this conference but has had no input into the arrangements or the content except the session on “Improving Influenza Vaccine Uptake” which has specifically been sponsored and arranged by Seqirus.

To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here Clinical Vaccines Network Virtual Conference 2020

Dr Alex Mentzer

Alexander Mentzer is a Group Leader at the Wellcome Centre for Human Genetics, University of Oxford, and an Academic Clinical Lecturer and Infectious Disease Physician based at the John Radcliffe Hospital, Oxford. Alex has led a number of studies aiming to understand genetic susceptibility to severe infectious disease and implementation of these findings at the clinical front line to improve outcomes for patients with severe infection presenting to hospital. Much of his recent work has been focused on COVID-19 and the development and validation of tests measuring immune responses to SARS-CoV2.

Top